Oppenheimer analyst Mark Breidenbach initiated coverage of Nurix Therapeutics with an Outperform rating and $25 price target. Nurix is developing a pipeline of targeted protein degraders and E3 ligase inhibitors and its lead program, NX-2127, has shown "clear evidence of activity" in heavily-pretreated chronic lymphocytic leukemia, or CLL, and diffuse large B-cell lymphoma, or DLBCL, patients, the analyst tells investors. The firm believes Nurix’s BTK-degrader franchise of NX-2127 and NX-5948 could "generate significant revenue in a wide range of oncology and autoimmune indications," it stated.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on NRIX:
- Down More Than 40%: 2 ‘Strong Buy’ Stocks That Are Too Cheap to Ignore
- Nurix Therapeutics price target lowered to $31 from $37 at Stifel
- Nurix Therapeutics, Inc. Earnings Report: Did it Beat Expectations?
- Nurix Therapeutics reports Q4 EPS (87c), consensus (79c)
- Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides a Corporate Update
